Q4 2024 Earnings Call Transcript March 17, 2025 Protalix BioTherapeutics, Inc. beats earnings expectations. Reported EPS is $0.09, expectations were $0.07. Operator: Good morning, ladies and gentlemen ...

PLX READ THE FULL PLX RESEARCH REPORT 2024 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 2024 financial and operational results in a March 17th, 2024 press ...

Insights into antibiotic–carrier interactions in the silk-fibroin-based nanoparticles and considerations on the formulation process greenness are limited. Hence, this work developed and characterized ...

Discover Protalix BioTherapeutics' Q4 2024 earnings insights, including record revenues, pipeline advancements, and future growth prospects.

以列线图的形式呈现该预测模型，用于定量预测慢乙肝患者接受PEG IFNα治疗48周后的HBsAg清除率。通过基线HBsAg水平、性别和肝硬化状态，可以初步简易评估患者接受PEG ...

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: ...

Mirvetuximab soravtansine improved overall survival over chemotherapy in patients with FRα-positive, platinum-resistant ovarian cancer.

Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® ...

肿瘤患者在治疗过程中常避免不了化疗，化疗药物不仅会抑制癌细胞生长，同时还抑制骨髓造血细胞（即肿瘤化疗常见的副作用骨髓抑制），骨髓抑制主要表现为白细胞、血小板、红细胞的数量下降，其中，白细胞的数量下降最为常见，白细胞的数量降低到一定程度（分级见图1）， ...

NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...

and is also exploring use of the drug in combination with current therapies including pegylated interferon (PegIFN) and its experimental immunotherapies. GSK licensed the drug from longstanding ...

Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S ®), an investigational folate receptor-alpha (FRα)-targeted, ...